Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Chronic kidney disease
•
Nephrology
•
Endocrinology
•
Primary Care
Do you recommend stopping a SGLT2i indefinitely if a patient with chronic kidney disease and diabetes develops euglycemic diabetic ketoacidosis?
Answer from: at Academic Institution
I would. In my opinion, the risk of ketoacidosis will outweigh the possible benefit from SGLTs.
Comments
at CommonSpirit
Absolutely, I would stop SGLT as one episode shoul...
at Atrium Health Wake Forest Baptist Medical Center
I would, depending on the individual patient with ...
12214
12216
Sign in or Register to read more
22632
Related Questions
How do you approach managing patients with diabetic kidney disease and proteinuria who develop hypoglycemia after initiation of a SGLT2 inhibitor?
Is your decision to prescribe empagliflozin for CKD patients without albuminuria influenced by a recent cost-utility analysis showing that empagliflozin was not cost-effective for this group?
Do you recommend patients with chronic kidney disease avoid supplements containing creatine?
How do the results of the ESPRIT trial, which evaluated the impact of an SBP target of <120 mmHg on preventing major cardiovascular events, influence your blood pressure management goals for hypertensive patients with diabetes or a history of stroke?
Would you start an SGLT2 inhibitor in patients with diabetic kidney disease who also have a history of prior toe amputation?
Is it a good practice to prescribe clonidine to take as needed for occasional severe blood pressure elevations?
Does vitamin D supplementation in primary hyperparathyroidism increase the risk of kidney stones?
At what serum bicarbonate level do you initiate alkali therapy for patients with chronic kidney disease?
Is there a role for monitoring PTH levels in patients with advanced chronic kidney disease who are receiving denosumab to assess for adynamic bone disease?
How do you approach vitamin D supplementation in patients with chronic kidney disease, given the findings that vitamin D2 supplementation may lead to decreased conversion of 25-hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3?
Absolutely, I would stop SGLT as one episode shoul...
I would, depending on the individual patient with ...